TRACRIUM PRESERVATIVE FREE Drug Patent Profile

When do Tracrium Preservative Free patents expire, and when can generic versions of Tracrium Preservative Free launch?

Tracrium Preservative Free is a drug marketed by Hospira and is included in one NDA.

The generic ingredient in TRACRIUM PRESERVATIVE FREE is atracurium besylate. There are sixteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the atracurium besylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tracrium Preservative Free

A generic version of TRACRIUM PRESERVATIVE FREE was approved as atracurium besylate by HIKMA on July 18^th, 1997.

Summary for TRACRIUM PRESERVATIVE FREE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	101
Patent Applications:	737
DailyMed Link:	TRACRIUM PRESERVATIVE FREE at DailyMed

US Patents and Regulatory Information for TRACRIUM PRESERVATIVE FREE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	TRACRIUM PRESERVATIVE FREE	atracurium besylate	INJECTABLE;INJECTION	018831-001	Nov 23, 1983		DISCN	Yes	No

Expired US Patents for TRACRIUM PRESERVATIVE FREE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hospira	TRACRIUM PRESERVATIVE FREE	atracurium besylate	INJECTABLE;INJECTION	018831-001	Nov 23, 1983	4,179,507

International Patents for TRACRIUM PRESERVATIVE FREE

See the table below for patents covering TRACRIUM PRESERVATIVE FREE around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	61485
Denmark	553676
Australia	506657
Guatemala	198400125	COMPUESTOS DE AMONIO CUATERNARIOS.
Singapore	73983
France	2334359
Kenya	3361	TETRAHYDROISOQUINOLINIUM MUSCLE RELAXANTS

TRACRIUM PRESERVATIVE FREE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Atracurium Besylate (TRACRIUM)

Introduction

Atracurium besylate, marketed under the brand name TRACRIUM, is a nondepolarizing, intermediate-duration skeletal neuromuscular blocking agent. It is widely used in anesthesia to facilitate muscle relaxation during surgical procedures and mechanical ventilation. Here, we delve into the market dynamics and financial trajectory of atracurium besylate.

Market Size and Growth

The atracurium market has been experiencing steady growth, driven by several key factors. As of 2023, the atracurium market was valued at USD 420.0 million and is projected to reach USD 694.9 million by 2033, with a Compound Annual Growth Rate (CAGR) of 5.3% during the forecast period from 2024 to 2033[3].

Driving Factors

Increasing Demand for Surgical Procedures

The rising number of surgical interventions globally is a primary driver of the atracurium market. This trend is attributed to an aging population and the increasing prevalence of chronic diseases that necessitate surgical interventions. As healthcare systems evolve and prioritize patient outcomes, the demand for effective neuromuscular-blocking agents like atracurium is expected to rise[3].

Advancements in Anesthesia Practices

Advancements in medical technologies and anesthesia practices have enhanced the role of atracurium in modern anesthesiology. Atracurium's intermediate duration of action and minimal side effects make it an essential component in standardized anesthesia protocols, ensuring consistent usage across various surgical settings[3].

Expanding Clinical Applications

Atracurium is valued for its ability to provide muscle relaxation during surgery without causing significant cardiovascular effects, making it suitable for patients with varying medical conditions. This versatility expands its clinical applications, further driving market growth[4].

Market Segmentation

By Type

Atracurium besylate injection dominates the market by type, reflecting its widespread use in surgical and intensive care settings[3].

By Units

The 5 mL segment holds a dominant market position by units, due to its optimal dosage convenience that meets diverse clinical needs. The 10 mL segment follows closely, catering to high-volume usage scenarios such as prolonged surgeries or patients requiring extended mechanical ventilation[3].

By End-User

Hospitals dominate the atracurium market demand, driving overall growth. The increasing prioritization of surgical outcomes and patient care in hospitals directly correlates with a higher utilization of atracurium[3].

Regional Dominance

North America dominates the atracurium market with a 35% market share, driven by advanced healthcare infrastructure and high surgical procedure rates[3].

Financial Trajectory

Revenue Projections

The projected growth from USD 420.0 million in 2023 to USD 694.9 million by 2033 indicates a robust financial trajectory for the atracurium market. This growth is supported by increasing consumer demand, advancements in medical technologies, and the expansion of healthcare infrastructure globally[3].

Investment and Development

Despite the positive financial outlook, market players face significant challenges, including the high costs associated with the development and approval of new drugs. Regulatory hurdles and stringent approval processes impose substantial financial burdens, impacting the pace at which new products can enter the market[3].

Challenges and Opportunities

Regulatory Hurdles

The development and approval of new neuromuscular-blocking agents are fraught with regulatory challenges. These hurdles can slow down market growth but also present opportunities for innovation and differentiation among market players[3].

Growing Consumer Demand

The healthcare sector's increasing demand for effective neuromuscular-blocking agents like atracurium presents a significant opportunity for manufacturers. Scaling up production and improving distribution networks can help meet the burgeoning needs of healthcare providers worldwide[3].

Latest Trends

Rising Demand in Hospital Settings

The demand for atracurium is expected to increase significantly in hospital settings, driven by the expansion of healthcare infrastructure and the prioritization of surgical outcomes. Hospitals are increasingly relying on atracurium to enhance patient care and operational efficiency[3].

Sustainability and Cost-Effectiveness

As healthcare systems focus on sustainability and cost-effectiveness, the market for atracurium is likely to benefit from its established efficacy and safety profile. Manufacturers can capitalize on this trend by emphasizing the long-term benefits and cost-effectiveness of atracurium in clinical settings[3].

Storage and Stability

Atracurium besylate injection requires specific storage conditions to maintain its potency. It should be refrigerated at 2°C to 8°C and used within 14 days if stored at room temperature. This ensures the drug remains effective and safe for use[1][4].

Conclusion

The atracurium market is poised for substantial growth, driven by increasing surgical procedures, advancements in anesthesia practices, and the rising prevalence of chronic diseases. Despite regulatory and financial challenges, the market offers significant opportunities for manufacturers to meet growing consumer demand and enhance patient outcomes.

Key Takeaways

• Market Growth: The atracurium market is expected to grow from USD 420.0 million in 2023 to USD 694.9 million by 2033, with a CAGR of 5.3%.
• Dominant Segments: Atracurium besylate injection and the 5 mL segment dominate the market by type and units, respectively.
• End-User Demand: Hospitals drive the majority of the demand for atracurium.
• Regional Dominance: North America holds a 35% market share.
• Challenges and Opportunities: Regulatory hurdles and growing consumer demand are key factors influencing market dynamics.

FAQs

What is the primary use of atracurium besylate in medical settings?

Atracurium besylate is used as an adjunct to general anesthesia to facilitate endotracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation[4].

What are the storage requirements for atracurium besylate?

Atracurium besylate should be refrigerated at 2°C to 8°C to preserve potency. It can be used within 14 days if stored at room temperature[1][4].

What drives the demand for atracurium in the market?

The demand for atracurium is driven by the increasing number of surgical procedures, advancements in anesthesia practices, and the rising prevalence of chronic diseases[3].

Which segment dominates the atracurium market by units?

The 5 mL segment dominates the atracurium market by units due to its optimal dosage convenience[3].

What are the projected revenue figures for the atracurium market by 2033?

The atracurium market is projected to reach USD 694.9 million by 2033, with a CAGR of 5.3% from 2024 to 2033[3].

Sources

1. PRODUCT MONOGRAPH TRACRIUM7 (Atracurium besylate)
2. PharmGKB - cisatracurium besylate
3. Atracurium Market Size, Share, Growth | CAGR of 5.3%
4. RxList - Tracrium (Atracurium Besylate): Side Effects, Uses, Dosage